Annual report
6545.TEDINET S100W4X4
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 142
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥5.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥4.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥401m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥230m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥411m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥271m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥146m | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥290m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥408m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥243m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥255m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥131m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥186m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥255m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥131m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥4.3bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥3.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥3.2bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥2.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥467m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥379m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥303m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥272m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥228m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥15m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥302m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥236m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥497m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥61m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥24m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥250m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥47.82 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.59 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.27 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.67 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.62 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥23.99 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.13 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.74 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥303.48 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥261.75 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥238.56 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥231.64 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 38.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.0% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 353 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 364 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 374 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 329 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥341m | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥2.1bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥404m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | −¥141m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥291m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥149m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥7m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥281m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥250m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥135m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥123m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥115m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥123m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥31m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥187m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥150m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥3.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.7bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.3bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.7bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.0bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥845m | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥362m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥104m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥343m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥21.65 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.19 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.66 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.85 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.08 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥21.1 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.62 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.91 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.29 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥12 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥228.4 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥244.17 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥222.67 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥232.38 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥190.07 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 41.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,427,771 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,427,771 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 54 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 172 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 202 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 296 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 319 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 33
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥5m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥463m |
| Health Care Solution Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥83m |
| Health Care Solution Businessreportable segment | employees | at 2025-03-31 | 196 pure |
| Health Care Solution Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Health Care Solution Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Health Care Solution Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥525m |
| Home Care Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥25m |
| Home Care Businessreportable segment | employees | at 2025-03-31 | 117 pure |
| Home Care Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Home Care Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Home Care Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥339m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥108m |
| —segment total | employees | at 2025-03-31 | 313 pure |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥864m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥26m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥531m |
| Health Care Solution Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥70m |
| Health Care Solution Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Health Care Solution Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.4bn |
| Health Care Solution Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥421m |
| Home Care Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥27m |
| Home Care Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Home Care Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Home Care Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥339m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥98m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥761m |
| Health Care Solution Businessreportable segment | employees | at 2025-03-31 | 19 pure |
| —segment total | employees | at 2025-03-31 | 19 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,339
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 77000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0143 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 71000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0132 | |
| Number of shares held | CurrentYearInstant | 2868000 | |
| Shareholding ratio | CurrentYearInstant | 0.5285 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 600 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 5424500 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 54245 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 2671 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 5427771 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 54245 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0001 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0001 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 65125000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 12.00 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | － | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000BeckKeiichiMember | 281894 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000FujisawaTakuMember | 224865 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000HoshinoKenjiMember | 69574 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000KanekoHiroomiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000KurodaKazumichiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000KinugawaShinyaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000SatoMasahikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33005-000WatanabeTatsuoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 576333 | |
| Audit fees reporting company | Prior1YearDuration | 37800000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 32000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 37800000 | JPY |
| Non audit fees total | Prior1YearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 32000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |